Mucoadhesive nanoemulsion enhances brain bioavailability of luteolin after intranasal administration and induces apoptosis to SH-SY5Y neuroblastoma cells

Diedrich, Camila; Zittlau, Isabella Camargo; Machado, Christiane Schineider; Fin, M. T.; Khalil, Najeh Maissar; Badea, Ildikó; Mainardes, Rubiana Mara

doi:10.1016/j.ijpharm.2022.122142

Cited by 18 publications

(13 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diedrich et al designed a chitosan-coated nanoemulsion loaded with Lu for potential brain-targeted delivery after intranasal administration. 90 The resulting NECh-LUT notably increased nasal mucosa permeability by nearly 6-fold, extended the half-life of Lu by about 10-fold, and enhanced the distribution of Lu in brain tissue by 4.4-fold. Remarkably, NECh-LUT effectively inhibited the growth of human neuroblastoma cell SH-SY5Y, highlighting its potential therapeutic value.…”

Section: Nanoemulsionsmentioning

confidence: 96%

“…Furthermore, intranasal drug delivery formulations, including chitosomes, nanoemulsions, and bilosomes, have been developed to facilitate brain-targeted drug delivery of Lu. 90,106,109 This approach increases bioavailability by facilitating the transport of drugs through the blood-brain barrier, offering an effective, non-invasive, and safe method of drug administration. This review also introduces the advancements and applications of Lu-loaded nano-scale drug delivery systems in the treatment of various diseases, as illustrated in Fig.…”

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

See 1 more Smart Citation

Nano-scale drug delivery systems for luteolin: advancements and applications

Shang,

Yang,

Deng

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Nanoemulsionsmentioning

confidence: 96%

Section: Conclusion and Future Perspectivesmentioning

confidence: 99%

Nano-scale drug delivery systems for luteolin: advancements and applications

Shang,

Yang,

Deng

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Therefore, the preparation of a mucoadhesive nasal preparation easily achieves this step. For example, rotigotine, asenapine maleate, luteolin, and teriflunomid are drugs that were formulated as intranasal mucoadhesive systems in a nanoemulsions form. The aim of all those preparations was to increase their retention time on the nasal mucosa, therefore increasing their brain availability.…”

Section: Strategies For Enhanced Brain Targetingmentioning

confidence: 99%

Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose–Brain Drug Delivery

Taha,

Shetta,

Nour

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

The intranasal route has proven to be a reliable and promising route for delivering therapeutics to the central nervous system (CNS), averting the blood−brain barrier (BBB) and avoiding extensive first-pass metabolism of some drugs, with minimal systemic exposure. This is considered to be the main problem associated with other routes of drug delivery such as oral, parenteral, and transdermal, among other administration methods. The intranasal route maximizes drug bioavailability, particularly those susceptible to enzymatic degradation such as peptides and proteins. This review will stipulate an overview of the intranasal route as a channel for drug delivery, including its benefits and drawbacks, as well as different mechanisms of CNS drug targeting using nanoparticulate drug delivery systems devices; it also focuses on pharmaceutical dosage forms such as drops, sprays, or gels via the nasal route comprising different polymers, absorption promoters, CNS ligands, and permeation enhancers.

show abstract

“…This provides a greater surface area for drug crossing through the membrane and into the brain [ 45 , 46 , 47 , 48 ]. For this reason, numerous chitosan-based nasal formulations have been proposed as drug delivery systems to the CNS, including chitosan-dopamine and chitosan-tyrosine conjugates for PD [ 49 ], chitosan hydrogels for drug delivery in AD [ 50 ], chitosan-poloxamer gel for anti-epileptic drug (AED) delivery [ 51 ], chitosan nanoemulsions for glioblastoma multiforme (GBM) therapies [ 52 ], and chitosan-poloxamer nanoemulsions for the treatment of cerebral ischemia [ 53 ]. While NPs can be synthesised from chitosan, it is commonly used as a surface coating to enhance mucoadhesion and particle transport across the nasal mucosa and into the brain.…”

Section: Nanotechnology For Bbb Crossingmentioning

confidence: 99%

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

et al. 2023

View full text Add to dashboard Cite

Nanomedicine is currently focused on the design and development of nanocarriers that enhance drug delivery to the brain to address unmet clinical needs for treating neuropsychiatric disorders and neurological diseases. Polymer and lipid-based drug carriers are advantageous for delivery to the central nervous system (CNS) due to their safety profiles, drug-loading capacity, and controlled-release properties. Polymer and lipid-based nanoparticles (NPs) are reported to penetrate the blood–brain barrier (BBB) and have been extensively assessed in in vitro and animal models of glioblastoma, epilepsy, and neurodegenerative disease. Since approval by the Food and Drug Administration (FDA) of intranasal esketamine for treatment of major depressive disorder, intranasal administration has emerged as an attractive route to bypass the BBB for drug delivery to the CNS. NPs can be specifically designed for intranasal administration by tailoring their size and coating with mucoadhesive agents or other moieties that promote transport across the nasal mucosa. In this review, unique characteristics of polymeric and lipid-based nanocarriers desirable for drug delivery to the brain are explored in addition to their potential for drug repurposing for the treatment of CNS disorders. Progress in intranasal drug delivery using polymeric and lipid-based nanostructures for the development of treatments of various neurological diseases are also described.

show abstract

Mucoadhesive nanoemulsion enhances brain bioavailability of luteolin after intranasal administration and induces apoptosis to SH-SY5Y neuroblastoma cells

Cited by 18 publications

References 88 publications

Nano-scale drug delivery systems for luteolin: advancements and applications

Nano-scale drug delivery systems for luteolin: advancements and applications

Versatile Nanoparticulate Systems as a Prosperous Platform for Targeted Nose–Brain Drug Delivery

Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery

Contact Info

Product

Resources

About